Generic Sweden AB (STO:GENI) Has Attractive Fundamentals

Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card!

Building up an investment case requires looking at a stock holistically. Today I’ve chosen to put the spotlight on Generic Sweden AB (STO:GENI) due to its excellent fundamentals in more than one area. GENI is a company with great financial health as well as a an impressive history of performance. Below, I’ve touched on some key aspects you should know on a high level. For those interested in digger a bit deeper into my commentary, take a look at the report on Generic Sweden here.

Outstanding track record with flawless balance sheet

GENI delivered a bottom-line expansion of 67% in the prior year, with its most recent earnings level surpassing its average level over the last five years. This illustrates a strong track record, leading to a satisfying return on equity of 24%. which is an optimistic signal for the future. GENI is financially robust, with ample cash on hand and short-term investments to meet upcoming liabilities. This suggests prudent control over cash and cost by management, which is a key determinant of the company’s health. Looking at GENI’s capital structure, the company has no debt on its balance sheet. It has only utilized funding from its equity capital to run the business, which is typically normal for a small-cap company. Investors’ risk associated with debt is virtually non-existent and the company has plenty of headroom to grow debt in the future, should the need arise.

OM:GENI Income Statement, May 23rd 2019
OM:GENI Income Statement, May 23rd 2019

Next Steps:

For Generic Sweden, there are three important aspects you should further research:

  1. Future Outlook: What are well-informed industry analysts predicting for GENI’s future growth? Take a look at our free research report of analyst consensus for GENI’s outlook.
  2. Valuation: What is GENI worth today? Is the stock undervalued, even when its growth outlook is factored into its intrinsic value? The intrinsic value infographic in our free research report helps visualize whether GENI is currently mispriced by the market.
  3. Other Attractive Alternatives : Are there other well-rounded stocks you could be holding instead of GENI? Explore our interactive list of stocks with large potential to get an idea of what else is out there you may be missing!

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned. Thank you for reading.